USFDA accepts Mylan's BLA for proposed biosimilar Trastuzumab

USFDA accepts Mylan's BLA for proposed biosimilar Trastuzumab
12-Jan-2017 08:56 MONEYCONTROL

The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.